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Rabbit IL-4 was expressed in the virulent standard laboratory strain (SLS) and the attenuated Uriarra (Ur) strain of myxoma virus with the
aim of creating a Th2 cytokine environment and inhibiting the development of an antiviral cell-mediated response to myxomatosis in infected
rabbits. This allowed testing of a model for genetic resistance to myxomatosis in wild rabbits that have undergone 50 years of natural
selection for resistance to myxomatosis. Expression of IL-4 significantly enhanced virulence of both virulent and attenuated virus strains in
susceptible (laboratory) and resistant (wild) rabbits. SLS-IL-4 completely overcame genetic resistance in wild rabbits. The pathogenesis of
SLS-IL-4 was compared in susceptible and resistant rabbits. The results support a model for resistance to myxomatosis of an enhanced innate
immune response controlling virus replication and allowing an effective antiviral cell-mediated immune response to develop in resistant
rabbits. Expression of IL-4 did not overcome immunity to myxomatosis induced by immunization.
D 2004 Published by Elsevier Inc.Keywords: Myxoma virus; Genetic resistance; IL-4; Rabbits; CoevolutionIntroduction
One of the best-studied examples of the coevolution of
a species with a novel pathogen is the introduction of
myxoma virus into the Australian wild population of
European rabbits (Oryctolagus cuniculus) and the subse-
quent 50 years of evolution of both pathogen and host.
Myxoma virus is a poxvirus (genus: Leporipoxvirus). The
native host of myxoma virus is the South American tapeti
(forest rabbit; Sylvilagus brasiliensis) or the North Amer-
ican brush rabbit (Sylvilagus bachmani). In its native
hosts, the virus causes a cutaneous fibroma at the inoc-
ulation site and minimal signs of clinical disease. How-
ever, in European rabbits, myxoma virus causes the
highly lethal disease myxomatosis.0042-6822/$ - see front matter D 2004 Published by Elsevier Inc.
doi:10.1016/j.virol.2004.02.031
* Corresponding author. CSIRO Sustainable Ecosystems, GPO Box
284, Canberra, ACT 2601, Australia. Fax: +61-2-62421764.
E-mail address: peter.kerr@csiro.au (P.J. Kerr).Because of the high lethality of myxoma virus, the
standard laboratory strain (SLS) was experimentally intro-
duced into the Australian wild rabbit population in 1950.
This release triggered a series of lethal epidemics of
myxomatosis, which are estimated to have reduced the
Australian rabbit population by as much as 95% (Wil-
liams et al., 1995). Since this introduction, there has been
ongoing coevolution of virus and host. This rapidly led to
the virus population being dominated by strains of re-
duced virulence that were more efficiently transmitted by
the mosquito vectors, and to strong selection for genetic
resistance to myxoma virus in the rabbit population
(reviewed in Fenner and Fantini, 1999; Kerr and Best,
1998).
This coevolution of host and pathogen has provided a
unique system to understand how introduction of a novel
pathogen into a naive mammalian host, in an outbred
natural system, on a continent-wide scale can drive the
evolution of both the host and the pathogen. This system
is unique in that the originally released strain of virus is
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susceptible hosts because these have never been selected
for resistance to myxoma virus, and wild rabbits can be
bred in captivity to study resistance. In addition, the
highly attenuated field strain of myxoma virus Uriarra-
2-53/1 (Ur) (Mykytowycz, 1953; Russell and Robbins,
1989) isolated in Australia in 1953, only 2 years after the
release of SLS, and derived from SLS, has been charac-
terized as a model attenuated virus.
The pathogenesis of the virulent SLS and attenuated Ur
strain of myxoma virus has been characterized in laboratory
(genetically susceptible) and wild (genetically resistant)
rabbits (Best and Kerr, 2000; Best et al., 2000). SLS kills
100% of laboratory rabbits with an average survival time of
10–12 days (Fenner et al., 1957; Robinson et al., 1999).
However, in wild rabbits, SLS killed only a small proportion
of infected rabbits although still causing severe clinical
myxomatosis. Similarly, Ur infection of laboratory rabbits
was characterized by a wide range of clinical signs from
severe to moderate and the occasional death, whereas in
wild rabbits it caused few or no clinical signs of myxoma-
tosis apart from the primary lesion at the inoculation site
(Best and Kerr, 2000).
In both resistant and susceptible rabbits, myxoma virus
replicated initially in MHC-II-positive cells in the upper
dermis and then spread to the epidermal cells and to the
draining lymph node. From this site, virus was dissemi-
nated to other lymphoid tissues, lungs, testis, and second-
ary skin sites. Lymphocytes were probably important for
dissemination of the virus. The key features of resistance
were the ability of the wild rabbits to delay spread of the
virus to distal tissues and to limit replication of the virus at
these sites, particularly the lymph node draining the
inoculation site. Replication in the skin was not initially
different in resistant or susceptible rabbits for SLS or Ur;
however, the subsequent inflammatory response at the site
of inoculation was quite different (Best and Kerr, 2000;
Best et al., 2000).
A model for resistance was proposed postulating that the
initial innate immune response to the virus in resistant
rabbits controls virus replication distal to the skin inocula-
tion site sufficiently for the rabbit to develop an effective
cell-mediated immune response. The model postulates that
resistant wild rabbits mount an effective innate antiviral
immune response dominated by natural killer (NK) cells,
interferons a/h, and the Th1 cytokines such as interferon-g
(IFN-g), TNF, and IL-12. In contrast, susceptible rabbits are
unable to control viral replication sufficiently to allow an
effective early cell-mediated response and that this would be
seen as an initial innate immune response dominated by Th2
cytokines such as IL-4 and IL-10 (Best and Kerr, 2000; Best
et al., 2000). This model was based to a large extent on
studies of ectromelia virus in resistant and susceptible mice
where resistant animals tend to produce Th1 cytokines such
as IL-2 and IFN-g while susceptible mice produced Th2
cytokines such as IL-4 and IL-10 (Karupiah, 1998). It hassubsequently been demonstrated that expression of IL-4 by
a recombinant ectromelia virus enables the virus to over-
come genetic resistance by suppressing both NK and
cytotoxic-T-lymphocyte (CTL) responses to ectromelia vi-
rus (Jackson et al., 2001).
To test this model for genetic resistance to myxoma
virus, we constructed recombinant myxoma viruses
expressing rabbit IL-4 either in a virulent SLS genetic
background or an attenuated Ur genetic background. These
viruses were each tested in laboratory and wild rabbits, and
the pathogenesis of SLS-IL-4 characterized. We demon-
strated that expression of rabbit IL-4 by myxoma virus
enhanced the virulence of the virus and overcame genetic
resistance in rabbits, and suggest a mechanism by which
this is occurring.Results
Virus construction and characterization
The plasmids used for construction of recombinant
viruses are shown in Fig. 1. The recombinant viruses
SLS-slp-IL-4, SLS-p28m-IL-4, and Ur-ZPB-p28m-IL-4
were isolated by repeated plaque purification until only
recombinant virus was present when tested by PCR. These
plaques were then amplified for virus stocks in RK13 cells.
Fig. 2 shows the results of PCR analysis for SLS-p28m-IL-
4. Sequence specific for the recombinant virus is amplified
in lane 2 using primers MJ2a-R2 and IL-4-start-Bgl that will
generate a 900-bp product from the recombinant virus and
primers MJ2a-R2 and TKF2 that will generate a 700-bp
product from the wild-type virus. Lane 2 shows that the
recombinant virus sequence is amplified while lane 3
indicates that no wild-type virus is present. Lane 4 is a
positive control for wild-type virus.
The expression of IL-4 by the recombinant viruses was
confirmed by immunoblotting using antipeptide antisera to
IL-4. Fig. 3 shows that three molecular weight species of
IL-4 were produced and that the IL-4 is produced in
much larger amounts under the control of the synthetic
late promoter in SLS compared to the p28m promoter in
Uriarra. However, no difference could be demonstrated
between the amounts of IL-4 produced by the synthetic
late promoter and the p28m promoter in the SLS back-
ground using further dilutions of protein or antibody (data
not shown).
The growth kinetics in cultured RK13 cells were exam-
ined for each of SLS, SLS-slp-IL-4, SLS-p28m-IL-4, and
Ur-ZPB-p28m-IL-4 to determine if the properties of the
recombinant viruses had been significantly altered in culture
compared to SLS. Fig. 4 shows that there was essentially no
difference in the growth kinetics of the three recombinant
viruses and SLS at either a multiplicity of infection (moi) of
3 or a moi of 0.1. The infected cell monolayers showed
virus-induced cytopathic effect (cpe) but there was less cpe
Fig. 1. Plasmid constructs used as transformation vectors. The IL-4 cDNA is under control of the strong synthetic late promoter (slp) in pUrTK11a-IL-4 (A),
which was used to construct SLS-slp-IL-4 recombinant virus. The IL-4 gene is under control of the modified p28 (p28m) promoter in pUrTK11-ZPB-IL-4 (B),
which was used to construct Ur-ZPB-p28m-IL-4 recombinant virus. The IL-4 gene is also under control of the p28m promoter in pUrTK-p28m-IL-4 (C), which
was used to construct SLS-p28m-IL-4 recombinant virus. Flanking myxoma virus sequences from the M059R to M062R genes are identified by their
abbreviations 59 to 62. TK = thymidine kinase. Unshaded areas in the GPT gene indicate noncoding sequence; black bars around the promoters indicate
noncoding sequences from vaccinia virus contained within the background plasmid. In each case, insertion of the foreign DNAwill be intergenic between the
M061 and M062 genes. See text for further details.
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compared to the other infections (data not shown).
Virulence assays in laboratory and wild rabbits
The virulence of each of the three IL-4-expressing
viruses was characterized in both laboratory rabbits (highly
susceptible to myxomatosis) and wild rabbits (highly resis-
tant to myxomatosis). To confirm the resistant phenotype of
the wild rabbit colony, a group of five wild rabbits was also
infected with SLS. Virulence was measured as the propor-Fig. 2. PCR analysis of SLS-p28m-IL-4. Individual plaques were amplified
in 96-well plates of RK13 cells. DNA from the resulting virus was analyzed
for purity by PCR. Lane 1: 100-bp markers. Lane 2: SLS-p28m-IL-4 virus
amplified to demonstrate recombinant virus amplification product of 900
bp. Lane 3: SLS-p28m-IL-4 virus amplified to demonstrate residual wild-
type virus (note no wild-type virus was detectable). Lane 4: SLS amplified
to demonstrate wild-type virus amplification product of 700 bp.tion of rabbits that died and the average survival time
(AST). These data are summarized in Table 1. As a
comparison, the results of recent testing of the SLS stock
in laboratory rabbits are shown (Robinson et al., 1999).
Only one of five wild rabbits infected with SLS died and
this was at 19 days (rabbit was euthanized). However, the
expression of IL-4 in SLS under the control of the synthetic
late promoter or the p28m late promoter was completely
lethal for both susceptible and resistant rabbits. Ur-ZPB-
p28m-IL-4 recombinant virus was completely lethal for
laboratory rabbits but only 1/6 wild rabbits infected with
this virus died.
The ASTs for those viruses that were lethal in 100% of
rabbits were compared by t test. SLS-slp-IL-4 and SLS-
p28m-IL-4 viruses had significantly lower survival times
compared to SLS and to Ur-ZPB-p28m-IL-4 (P < 0.001).
SLS had a lower AST than Ur-ZPB-p28m-IL-4 in labora-
tory rabbits (P < 0.002). SLS-slp-IL-4 had a significantly
lower AST in laboratory rabbits compared to wild rabbits
(P < 0.01) but there was no significant difference in AST
between wild and laboratory rabbits infected with SLS-
p28m-IL-4.
Rectal temperatures were measured daily as an indica-
tion of the progress of the disease. Fig. 5 shows that wild
rabbits infected with SLS had a sustained mean rectal
temperature of z40 jC from day 4 to day 16 after which
mean temperature dropped to the normal range. In con-
trast, both wild and laboratory rabbits infected with SLS-
Fig. 3. Immunoblot analysis of concentrated supernatants from RK13 cells infected with Ur-ZPB-p28-IL-4, SLS-p28m-IL-4, SLS-slp-IL-4, and SLS, showing a
complex of three bands (arrows) at approximately 15–17 kDa. Equivalent amounts of concentrated supernatant were loaded in each lane.
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normal by day 7. Mean rectal temperatures for wild and
laboratory rabbits infected with SLS-p28m-IL-4 were
similar to those for SLS-slp-IL-4 (data not shown). The
group of laboratory rabbits infected with Ur-ZPB-p28m-
IL-4 had only 1 day when mean rectal temperature was
z40 jC and mean temperatures fell below normal after
day 10. Wild rabbits infected with Ur-ZPB-p28m-IL-4
maintained mean clinical temperatures within the normal
range and although individual rabbits developed fevers
the mean rectal temperature was never z40 jC.
All five wild rabbits infected with SLS developed
myxomatosis and became quite ill, but from about day
12 after infection four of the five began to make a rapid
recovery. The fifth rabbit, while controlling many of the
signs of virus infection, continued to lose weight and
was euthanized at day 19. Autopsy revealed pneumonia
in the anterior lobe of one lung. The clinical signs in
laboratory and wild rabbits infected with SLS-slp-IL-4Fig. 4. Growth kinetics in RK13 cells of SLS, SLS-slp-IL-4, SLS-p28m-IL-4 and U
ZPB-p28m-IL-4; 5, SLS-slp-IL-4; w , SLS.are summarized in Table 2. Most laboratory rabbits
developed early signs of myxomatosis, but late in
infection some also showed other clinical signs such as
intense muscle trembling, particularly on handling, loss
of placing reflexes in the front legs, respiratory difficulty,
and coma. The classical signs of closed, pus-filled eyes
and mucopurulent discharge from the nose were absent.
There were fewer clinical signs in wild rabbits than in
laboratory rabbits and these developed later. Those that
survived long enough developed similar clinical signs to
the laboratory rabbits infected with SLS-slp-IL-4 (Table
2). At autopsy, the most prominent features were fluid
dripping from the lungs in some cases, and in some
rabbits small 1–2 mm gastric ulcers and 2–5 mm
pyloric ulcers, as well as the more typical findings of
myxomatosis such as enlarged lymph nodes and the
glistening mucoid swelling in the cut surface of the
dermis and thickening of the epidermis at the inoculation
site. The clinical and autopsy findings for SLS-p28m-IL-r-ZPB-p28m-IL-4. (A) moi = 0.1. (B) moi = 3.D, SLS-p28m-IL-4; , Ur-
Table 1
Virulence of recombinant viruses in laboratory (susceptible) and wild
(resistant rabbits)
Laboratory rabbits Wild rabbits
Mortality ASTa
(SD)
(days)
Range
(days)
Mortality AST
(SD)
(days)
Range
(days)
SLS 30/30b 11.1 (0.9) 9.6–12.6 1/5 19 n/a
SLS-slp-
IL-4
6/6 7.1 (0.6) 6.5–8 10/10 8.4 (0.8) 7.5–9.75
SLS-
p28m-
IL-4
6/6 7.1 (0.5) 6–7.5 6/6 7.7 (1.2) 6–9.5
Ur-ZPB 0/12c n/a n/a nt nt nt
Ur-ZPB-
p28m-
IL-4
9/9 12.6 (1.7) 10.5–15.5 1/6 16.5 n/a
nt—not tested; n/a—not applicable.
a Average survival time (AST). Standard deviation (SD) is shown in
brackets.
b Data for laboratory rabbits are from a recent test of this virus stock
(Robinson et al., 1999).
c Data from Kerr et al. (1999).
Table 2
Clinical signs in laboratory and wild rabbits infected with SLS-slp-IL-4
SLS-slp-IL-4 Laboratory rabbits Wild rabbits
Day 2 5/6 rabbits had
0.5–1.5-cm-diameter
primary lesion at
inoculation site.
3/6 rabbits had a red spot at
the inoculation site. At day
3, all rabbits had a raised,
pale pink 1-cm-diameter
swelling at the inoculation
site.
Day 4 6/6 rabbits had a
1–2.5-cm-diameter lesion
at inoculation site. 3/6
rabbits had rectal
temperatures z40 jC.
Swellings at inoculation
sites were 1.5–2 cm in
diameter.
Day 5 2/6 rabbits had thickened
ears; 2/6 rabbits had rectal
temperatures z40 jC.
Similar to day 4.
Day 6 One rabbit had an extended
head and neck with deep
slow respiration, a wet chin
and thick drooping ears.
One rabbit had temperature
z40 jC and one <38 jC.
Several rabbits had small
secondary lesions on the
eyelids and slight
inflammation of the
anogenital region. Two
rabbits died overnight and a
third was moribund and
euthanized.
Slight redness of eyelids
noted in two rabbits; 5/6
had rectal temperatures
z40 jC.
Day 7 All rabbits died between
day 6 and 8. Clinical signs
included slight eyelid
swelling, muscular
trembling of face and jaw,
and precipitous drop in
rectal temperature. One
rabbit was semiconscious
sitting on his chest with
head on floor of cage.
Lesions at inoculation site
3–4 cm in diameter. Some
redness of the eyelids. Two
rabbits were uncoordinated
and trembling; both had
rectal temperatures below
normal. Both were found
dead the next morning.
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SLS-slp-IL-4 (data not shown).
Laboratory rabbits infected with Ur-ZPB-p28m-IL-4 de-
veloped clinical myxomatosis and all died. However, wild
rabbits retained resistance to this virus. Infection of six wild
rabbits caused moderate to severe myxomatosis with only
one death, at day 16.5, and recovery of the remaining five
rabbits. Table 3 compares the clinical signs of Ur-ZPB-
p28m-IL-4 infection of laboratory and wild rabbits.
SLS and Ur have been previously compared in laboratory
and wild rabbits and clinical and pathological descriptions
are given in Best and Kerr (2000).Fig. 5. Mean rectal temperatures of groups of wild rabbits infected with
SLS and wild and laboratory rabbits infected with SLS-slp-IL-4 or Ur-ZPB-
p28m-IL-4. , Ur-ZPB-p28-IL-4 laboratory rabbits; *, Ur-ZPB-p28m-IL-4
wild rabbits; 5, SLS-slp-IL-4 wild rabbits; E, SLS-slp-IL-4 laboratory
rabbits; y, SLS wild rabbits.
Handling induced severe
muscular twitching and
jerking.
Day 8 to
day 10
All rabbits dead. Two rabbits had subnormal
temperatures. Others had
rapid respiration, were
uncoordinated, and had
shivering and muscle
twitching. One rabbit was
euthanized and another died
overnight. All rabbits dead
by day 10.Pathogenesis trials of SLS-slp-IL-4
Nine laboratory and 12 wild rabbits were injected with
1000 pfu of SLS-slp-IL-4 in the dorsal skin of the right hind
foot. Three rabbits from each group were killed at 2, 4, 6,
and for wild rabbits, 8 days after inoculation. The major
autopsy findings were the typical mucoid thickening of the
dermis and swelling of the epidermis at the inoculation site
and the swelling of the draining and contralateral lymph
Table 3
Clinical signs in laboratory and wild rabbits infected with Ur-ZPB-
p28m-IL-4
Ur-ZPB-
p28m-
IL-4
Laboratory rabbits Wild rabbits
Day 2 Slight pinkness at inoculation
site in 3/9 rabbits at 48 h; by
72 h, all rabbits had 0.5–1.0-
cm-diameter primary lesions.
On day 3, 2/6 rabbits had a
slight skin thickening and
pinkness at the inoculation site.
Day 4 Primary lesions up to 3 cm in
diameter.
All rabbits had some reaction
at the inoculation site. One
rabbit had a rectal temperature
of 40 jC.
Day 6 Increased rectal temperature
in 1/9 rabbits on day 6. By
day 7, 5/9 rabbits had
temperatures ranging from
40–41.4 jC. Two rabbits
had slight swelling of the
anogenital area and one rabbit
had red eyelid margins.
Primary lesions were up to
3.5 cm in diameter.
Primary lesions were
1.5–3 cm in diameter. 1/6
rabbits had slightly swollen
eyelid margins. By day 7, 5/6
rabbits had mildly thickened
eyelid margins and 3/6 had
rectal temperatures z 40 jC.
Day 8 All rabbits showing some
signs of disseminated
myxomatosis: red eyelid
margins, small secondary
lesions, thickened ears,
anogenital swelling, and
slight ocular discharge. By
day 9, these signs were
more severe.
All rabbits had clinical signs
of mild myxomatosis such as
swollen eyelids and anogenital
swelling. Primary lesions were
up to 4.5 cm in diameter. By
day 9, primary lesions were up
to 6 cm in diameter.
Day 10 Nasal obstruction was
occurring; slight scrotal
oedema was noted in the
males. One rabbit died
between day 10 and day 11
and clinical signs became
more severe. Four rabbits had
subnormal temperatures and
died overnight.
Primary lesions were very
swollen-up to 8–10 cm in
diameter. Rabbits were starting
to group into those with mild
and those with moderate
clinical signs of myxomatosis.
By day 11, eyelids were very
swollen but there was little or
no ocular discharge.
Day 12 One rabbit with severe
clinical myxomatosis and
subnormal temperature
(35.3 jC) was euthanized.
Survivors ranged from
alert to very depressed.
Clinical signs started to
resolve; primary lesions were
becoming circumscribed and
starting to scab. Slight
snuffling in one rabbit. At day
13, this slow resolution of
clinical signs was more
obvious but one rabbit still
had severe myxomatosis.
Day 14 Two surviving rabbits
were very quiet with shallow,
slow respiration, subnormal
temperatures (34 and
35.8 jC), quite severe
myxomatosis but
responsive to handling.
One rabbit still very ill
although anogenital swelling
was resolving, another snuf-
fling
and quiet. Primary lesions
still very large but resolving.
Day 16 All rabbits dead or
euthanized.
Sick rabbit had temperature
of 37.1 jC and was euthanized.
Primary lesions resolving but
still 3.5–7 cm in diameter.
Day 20 Remaining sick rabbit
clinically recovering. Other
rabbits recovering. Primary
lesions resolved to scabs.
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not typical of myxomatosis was the presence of small 1–2
mm ulcers scattered in the gastric mucosa, pylorus, and
occasionally in the mucosa of the upper duodenum. Similar
ulceration had been noted in autopsies performed on rabbits
that died during the virulence tests with recombinant viruses
expressing IL-4.
To allow a direct indication of the range of results, titers
of virus in each tissue for each individual rabbit at each time
point are shown in Fig. 6. To avoid cluttering the graph,
mean titers have not been shown but are easily interpolated
by inspection. At day 2 after infection, virus titers in the skin
at the inoculation site of laboratory rabbits infected with
SLS-slp-IL-4 ranged from 6.1 to 7.0 log10 pfu/g of tissue. In
wild rabbits infected with SLS-slp-IL-4, virus was unde-
tectable at this time in two rabbits and a third rabbit had a
titer similar to the laboratory rabbits. By day 4, there were
essentially no differences in skin titers at the inoculation site
between laboratory and wild rabbits (Fig. 6A). In laboratory
rabbits, virus was detectable in distal skin at all time points
but at low titers (2.9–4.7 log10 pfu/g). In contrast, in wild
rabbits, no virus was detectable in distal skin before day 6
and at this time the titers were similar to laboratory rabbits.
However, at day 8 in wild rabbits, distal skin titers ranged
from 5.3 to 7.3 log10 pfu/g of skin (Fig. 6B).
The popliteal lymph node drains the inoculation site; at
day 2, virus titers ranged from undetectable in one rabbit to
5.1 log10 pfu/g in laboratory rabbits but virus was undetect-
able in all three wild rabbits. At day 4, these figures were
6.8–7.2 log10 pfu/g in laboratory rabbits and 6.2–6.4 log10
pfu/g in wild rabbits. At day 8, the titers in wild rabbit
draining lymph nodes were 9 log10 pfu/g (Fig. 6C). Simi-
larly, virus was detectable in contralateral lymph nodes at all
time points in laboratory rabbits and reached 6.8 log10 pfu/g
by day 6. In wild rabbits, virus was not detectable until day
4 but reached 6 log10 pfu/g at day 8 (Fig. 6D).
Laboratory rabbits infected with SLS-slp-IL-4 had virus
detectable in the lung by day 4. In contrast, it was day
8 before virus was detected in the lung of two of three wild
rabbits infected with SLS-slp-IL-4, although these titers
were high (Fig. 6E). Virus was not found in the spleen
before day 6 (Fig. 6F). Virus was occasionally detectable in
brains of infected laboratory rabbits but the titers were low
and inconsistent. However, in one wild rabbit, which died
before autopsy on day 8, high titers were found in the brain
(Fig. 6G). This rabbit also had similar titers in lung and
spleen.
Testing whether SLS-slp-IL-4 could overcome pre-existing
immunity
Expression of murine IL-4 in ectromelia virus has been
shown to overcome pre-existing immunity, from vaccina-
tion, to mousepox (Jackson et al., 2001). To determine
whether myxoma virus expressing IL-4 was able to over-
come pre-existing immunity to myxoma virus, eight labo-
Fig. 6. Virus titers in tissues from wild or laboratory rabbits infected with
SLS-slp-IL-4. Log10 virus titers for each individual rabbit are shown in each
panel. (A) Skin at inoculation site. (B) Contralateral skin. (C) Draining
lymph node. (D) Contralateral lymph node. (E) Lung. (F) Spleen. (G)
Brain. Solid diamonds (y) indicate laboratory rabbits and open squares (5)
indicate wild rabbits.
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immunogenic recombinant virus Ur-HA (Kerr and Jackson,
1995). All rabbits developed a primary lesion at the inoc-
ulation site and one rabbit developed disseminated small
secondary lesions over the face. None of the rabbits
appeared clinically ill. Four of these rabbits were challenged
6 weeks later with 1000 pfu of SLS-slp-IL-4 and four with
1000 pfu of SLS and all rabbits were monitored for clinical
signs of myxomatosis. There were no differences between
the rabbits challenged with SLS and the rabbits challenged
with SLS-slp-IL-4. All rabbits developed a 1–1.5 cm lesion
at the challenge inoculation site within 24–48 h. This
increased in size up to 2-cm diameter by day 3 but had
resolved by day 5. No clinical signs of myxomatosis were
observed, and there was no rise in rectal temperatures
following either challenge.
Four of the rabbits were retained and challenged again
with SLS-slp-IL-4 29 weeks after the original vaccination.
This time, the rabbits developed a raised lesion 0.5–1 cm in
diameter at the inoculation site 24–48 h after challenge but
there were no signs of myxomatosis. The swelling at the
inoculation site began to scab and resolve by day 4 after
challenge.
Thus, expression of IL-4 was not able to overcome
immunity to myxomatosis in outbred laboratory rabbits at
doses at the high end of what might be delivered by a
mosquito (Fenner and Ratcliffe, 1965). The use of higher
doses was not investigated.
Oral delivery trials
Oral delivery of myxoma virus does not normally lead to
successful infection. However, because of the high lethality
of SLS-slp-IL-4 and its ability to overcome genetic resis-
tance, we investigated whether this virus had changed its
pathogenesis sufficiently to infect rabbits following oral
delivery. This would potentially allow the use of bait
containing the virus as a rabbit-specific biocide. We dosed
six laboratory rabbits with 50,000 pfu of SLS-slp-IL-4 in a
200-Al volume into the cheek pouch. None of the rabbits
developed clinical signs of myxomatosis or increased rectal
temperatures (data not shown). The trial was repeated, this
time using the same dose of virus in a 10-Al volume
delivered inside the lower lip. Again, no signs of myxoma-
tosis were observed and none of the rabbits sero-converted
(data not shown). Thus expression of IL-4 did not enhance
oral infection by myxoma virus. Therefore, we concluded
that this virus would have no practical role as a rabbit bait
unless used on highly abrasive foodstuffs that inoculated
virus directly into the tissues of the mouth or pharynx.Discussion
Australian wild rabbits have developed substantial resis-
tance to myxomatosis over 50 years of coevolution (Best
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and Douglas, 1961; Marshall and Fenner, 1958). The
pathogenesis of this resistance has previously been exam-
ined using a model of virulent virus SLS and attenuated
virus Ur (Best and Kerr, 2000; Best et al., 2000). Based on
these pathogenesis studies, it was predicted that resistance
depended on the ability of the innate immune response in
wild rabbits to control the virus sufficiently for the rabbit to
develop an effective adaptive immune response (Kerr and
McFadden, 2002). It was also suggested that this might
manifest as a Th1 cytokine response in resistant rabbits and
a Th2 cytokine phenotype in susceptible rabbits.
To test these predictions, we conducted a manipulative
experiment to shift the cytokine environment in resistant or
susceptible rabbits toward a Th2 state. This was done using
recombinant myxoma viruses expressing the Th2 cytokine
rabbit IL-4 under two different late promoters and in a
virulent SLS background and a highly attenuated Ur-ZPB
background. As would be predicted from the results of
previous studies with poxviruses expressing IL-4 (Andrew
and Coupar, 1992; Jackson et al., 2001; Sharma et al.,
1996), the expression of IL-4 enhanced the virulence of
SLS and the recombinant SLS viruses expressing IL-4 were
able to overcome genetic resistance in wild rabbits. In
contrast, most wild rabbits infected with the parental SLS
virus were able to survive the infection.
Although Ur-ZPB is a very attenuated virus (Kerr et
al., 1999), Ur-ZPB-p28m-IL-4 was lethal in all infected
laboratory rabbits. However, in contrast to the results with
SLS-p28m-IL-4, most wild rabbits survived infection with
Ur-ZPB-p28m-IL-4, albeit with clinical signs of severe
myxomatosis. Thus, in wild rabbits, expression of IL-4 in
the Ur-ZPB background caused similar mortality to wild-
type SLS.
Expression of foreign genes between the M061 and
M062 genes in Ur has resulted in further attenuation of this
virus (Kerr and Jackson, 1995; Kerr et al., 1999) but
whether this was caused by the insertion at this site or by
the particular gene expressed has not been determined. It has
also been demonstrated that expression of foreign genes in
this site in SLS leads to significant attenuation of the virus
(S. Junankar, P.J. Kerr, B.H. van Leeuwen, unpublished
data). Thus, IL-4 expression has been able to overcome any
attenuation due to genetic modification of Ur or SLS,
increase virulence beyond that of the parental virus, and
overcome genetic resistance to myxoma virus.
Our prediction when starting this study was that IL-4
would diminish the ability of the resistant rabbits to mount
an effective cell-mediated immune response to myxoma
virus. However, if as we predicted, resistance was mediated
by the innate immune response or other cellular factors, we
expected that wild rabbits would have lower titers of virus
than laboratory rabbits at early time points after infection
but this difference would be lost later in infection due to the
deviation away from a cell-mediated immune response
induced by IL-4.When virus titers were measured in tissues of wild and
laboratory rabbits infected with SLS-slp-IL-4, it was clear
that at early time points wild rabbits did have lower titers of
virus than laboratory rabbits (see Fig. 6).
Taken together, the titers of virus tend to confirm that
wild rabbits were able to control SLS-slp-IL-4 replication at
early time points more effectively than laboratory rabbits.
This is similar to previous results for trials with SLS or Ur
(Best and Kerr, 2000). However, in the skin, at the inocu-
lation site, and in the draining lymph node, these differences
were largely overcome by day 4 after infection with SLS-
slp-IL-4. Similarly, SLS-slp-IL-4 was slower to disseminate
to distal tissues in wild rabbits compared to laboratory
rabbits but once at the distal tissues, it was able to replicate
to similar titers. This is in strong contrast to the previous
results with SLS where the virus was not only slower to
disseminate to distal tissues in wild rabbits compared with
laboratory rabbits, but then replicated to lower titers at these
sites (Best and Kerr, 2000).
These results support a conceptual model for resistance
to myxomatosis whereby myxoma virus replication is ini-
tially limited at tissues distal to the skin inoculation site by
an enhanced innate immune response or other cellular
factors that are able to partially overcome the modulation
of the immune response normally induced by myxoma virus
(Kerr and McFadden, 2002). This would favor the devel-
opment of an effective cell-mediated immune response
involving Th1 cells and cytotoxic T cells that control virus
replication from day 4 onwards (Best et al., 2000; Kerr and
McFadden, 2002).
Similar results have been reported in mice when murine
IL-4 was expressed in recombinant ectromelia virus. The
recombinant virus caused lethal infection in inbred strains of
mice that were normally resistant to mousepox and able to
control replication of ectromelia virus distal to the skin
inoculation site. Expression of IL-4 by ectromelia virus
induced both downregulation of innate NK cell activity
and suppression of CTL activity (Jackson et al., 2001).
Because there are as yet no convenient methods for exam-
ining CTL and NK responses in outbred rabbits, direct
measurement of immune deviation could not be done in
our study.
A quite striking finding reported by Jackson et al (2001)
was that the ectromelia virus expressing IL-4 was able to
overcome immunity induced by vaccination of mice by an
attenuated virus strain. Following challenge with ectromelia
virus expressing IL-4, 60% of vaccinated mice died. A
myxoma virus that could overcome pre-existing immunity
as well as genetic resistance might have major advantages as
a biological control agent for rabbits. However, SLS-slp-IL-
4 was unable to overcome pre-existing immunity when
injected in a dose at the extreme high end of what might
be delivered by a mosquito. This indicated that there was
either a major difference in the immune deviation caused by
myxoma virus expressing IL-4 in rabbits and ectromelia
virus expressing IL-4 in mice or that the ectromelia vacci-
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virus vaccine. There is also a formal possibility that the use
of a late promoter to drive IL-4 expression in myxoma virus
and the use of an early or late promoter in ectromelia virus
may have led to a difference at challenge. Whether other
poxviruses expressing IL-4 can overcome vaccination has
not been examined.
The use of myxoma virus as a biological control for
rabbits in Australia has been well reviewed (Fenner and
Fantini, 1999). It is clear from the biology of the disease that
selection for successful field strains of myxoma virus is
driven by arthropod transmission of virus and that trans-
mission is most successful with virus strains that are able to
cause significant disease with high mortality rates but which
allow rabbits to survive for long periods before succumbing
(Fenner, 1983; Kerr et al., 2003; Mead-Briggs and Vaughan,
1975). Although recombinant SLS viruses expressing IL-4
are highly lethal in Australian wild rabbits, despite genetic
resistance, and therefore potentially attractive for biological
control, they would be unlikely to compete successfully in
the field because the rabbits die very quickly following
infection, thus preventing further transmission.
There was a formal possibility that expression of IL-4 by
recombinant myxoma viruses was lethal because of direct
toxic effects of the cytokine on tissues such as liver and
lungs rather than its action in immune deviation (Andrew
and Coupar, 1992; Guillot et al., 2001; Huaux et al., 2003).
We attempted to address this in two ways, firstly by placing
the IL-4 gene under the control of the p28m promoter rather
than the synthetic late promoter (slp). Based on the results
reported for these two promoters by Davison and Moss
(1989), we expected that this would reduce expression of
IL-4 to 20% of the levels obtained with the slp. However, in
the SLS background, we could not detect any difference in
the amounts of IL-4 produced by SLS-slp-IL-4 and SLS-
p28m-IL-4 and there was no difference in the lethality of the
two viruses. The second approach was to express IL-4 in a
very highly attenuated strain of myxoma virus Ur-ZPB
under the control of the p28m promoter. This led to a
reduction in IL-4 expression compared to the SLS back-
ground. The Ur-ZPB-p28m-IL-4 virus was highly lethal in
laboratory rabbits but was much less lethal in wild rabbits
although causing severe myxomatosis. However, the lower
virulence in wild rabbits could also be associated with
reduced viral replication in wild rabbits compared to labo-
ratory rabbits and thus potentially less IL-4 production in
wild rabbits. Thus, we could not formally discard the
hypothesis that IL-4 was having a direct toxic effect.
However, comparing the titers of SLS-slp-IL-4 in wild
rabbits and those from SLS-slp-IL-4-infected laboratory
rabbits, it was clear that IL-4 was suppressing virus control
mechanisms and allowing replication of myxoma virus to
high titers in otherwise resistant wild rabbits. This is the
best direct evidence that IL-4 expression is overcoming
genetic resistance through an immune deviation mecha-
nism rather than through direct toxicity. Interestingly, titersof virus in laboratory rabbits were not increased above
what would have been expected from infection with SLS.
This may well be because the significant tissue destruction
of lymphoid tissues that occurs with SLS infection in
laboratory rabbits (Best et al., 2000) limits the amount of
viral replication that can occur but this has not yet been
examined for SLS-slp-IL-4.
This model of enhanced viral virulence due to immune
deviation is indirectly supported by clinical descriptions of
infections of rabbits with the highly lethal Californian
strains of myxoma virus (Fenner and Ratcliffe, 1965). These
viruses cause death in laboratory rabbits with an AST of 9.2
days and very few clinical signs of myxomatosis but signs
of central nervous system dysfunction similar to those
described here. Similar clinical signs of central nervous
system dysfunction, coma, and pulmonary edema are also
reported from laboratory rabbits infected with highly lethal
Australian strains of myxoma virus that have evolved to
transmit in populations of genetically resistant rabbits and
are more virulent than SLS (Kerr et al., 2003).
In conclusion, we have demonstrated that expression of
the Th2 cytokine IL-4 by myxoma virus enhances virulence
and overcomes genetic resistance to myxoma virus. This is
most likely due to immune deviation induced by IL-4
preventing development of an effective CTL response and
possibly due to decreased NK cell activity. The predicted
role of the innate immune system in resistance is also
supported by these studies. Thus, the use of immune
deviation has provided a useful tool for further detailed
studies into the mechanism of genetic resistance selected in
a naive outbred species following the introduction of a novel
pathogen.Methods
Virus strains and cell lines
The SLS stock used in this study was derived from a
freeze-dried rabbit tissue stock produced in 1953 that was
obtained from Professor Frank Fenner, John Curtin School
of Medical Research, Australian National University. This
virus was subsequently passaged twice in RK13 cells and
then twice in rabbits, and a rabbit testis stock was produced.
SLS has Grade 1 virulence for rabbits with an average
survival time of <13 days (Fenner et al., 1957). This has
been confirmed for virus from this stock (Robinson et al.,
1999). Ur was derived from the Uriarra/2-53/1 isolate
(Mykytowycz, 1953) by plaque purification (Russell and
Robbins, 1989). The virus is of grade 5 virulence, with all
laboratory rabbits developing myxomatosis but most even-
tually recovering from infection (Best and Kerr, 2000; Kerr
et al., 1999). Ur-HA is a recombinant Ur strain of myxoma
virus expressing the influenza virus hemagglutinin and
which does not cause clinical myxomatosis (Kerr and
Jackson, 1995).
P.J. Kerr et al. / Virology 324 (2004) 117–128126Virus stocks were cultured in RK13 cells in minimal
essential medium (MEM) (GibcoBRL) supplemented with
10% fetal calf serum, 200 units/ml penicillin, and 100 Ag/ml
streptomycin in an atmosphere of 5% CO2 in air at 37 jC.
Viruses were titered by plaque assays in duplicate on Vero
cell monolayers cultured in the same medium plus 2.5 Ag/ml
of amphotericin B. Titers were expressed as plaque forming
units per milliliter of culture (pfu/ml).
Transfer plasmid constructs
The plasmid pUrTK11a-IL-4 was constructed using
pUrTK11a as the starting plasmid. pUrTK11a (Jackson et
al., 1998) is a modification of pUrTK11 (Kerr and Jackson,
1995) in which the poxvirus p11 late promoter is replaced
with the optimized vaccinia virus strong synthetic late
promoter (slp) (Davison and Moss, 1989). The virus se-
quence in this plasmid is from the Ur strain of myxoma
virus (Jackson and Bults, 1992). There is only one nucle-
otide difference between the Ur sequence in this plasmid
and the equivalent region in the published Lausanne (Brazil/
Campinas 1949) strain of myxoma virus (Cameron et al.,
1999). This is an A > T transversion in the third position of
codon 41 in the M061 gene leading to a conservative Lys >
Asn amino acid change. Given this degree of conservation
and that Ur is directly derived from SLS, it was assumed
that the SLS and Ur sequence were highly unlikely to differ
in this region.
The rabbit IL-4 cDNA (Perkins et al., 2000) was
inserted into EcoRI–SalI-cut pUrTK11a. The resulting
plasmid (Fig. 1A), and those described below, also
contain the E. coli gpt gene under the control of the
poxvirus p7.5 early or late promoter to enable selection
for mycophenolic acid resistance. Flanking sequences
from the myxoma virus TK (M061R) and M062R genes
enable insertion of the foreign sequences intergenically
between these two genes. This plasmid was used to make
the SLS-slp-IL-4 recombinant virus.
pUrTK11-ZPB (Kerr et al., 1999) was used to con-
struct pUrTK11-ZPB-IL-4 by insertion of the rabbit IL-4
cDNA under the control of a modified p28 vaccinia virus
late promoter (p28m). This modified promoter (CACTTT-
TTTTTCTTCTCTAAAT) is described by Davison and
Moss (1989) as 20 times as strong as the native p28
promoter and about a fifth the strength of the synthetic
late promoter. The p28m promoter, made by annealing
two complementary oligonucleotides with restriction site
overhangs, was cloned immediately upstream of the IL-4
cDNA contained in another plasmid in use in our
laboratory (unpublished results). The p28m-IL-4 cassette
was excised from this plasmid and cloned into the SalI
site of pUrTK11-ZPB. The resulting plasmid (Fig. 1B)
also contains the rabbit zona pellucida B gene under the
control of the p11 late promoter (Davison and Moss,
1989), and was used to make the Ur-ZPB-p28m-IL-4
recombinant virus.To make a recombinant SLS-IL-4 virus in which
IL-4 expression is controlled by the p28m late pro-
moter, we constructed the plasmid pUrTK-p28m-IL-4
(Fig. 1C). This was achieved by deleting p11-ZPB
from pUrTK11-ZPB and replacing it with p28m-IL-4,
which was amplified by PCR from pUrTK11-ZPB-IL-4
above.
Preparation of recombinant myxoma viruses
Isolation of recombinant myxoma viruses was as
previously described (Kerr et al., 1999). Briefly,
RK13 cells were infected with either SLS (for SLS-
slp-IL-4, SLS-p28m-IL-4) or Ur (for Ur-ZPB-p28m-IL-
4) at a multiplicity of infection (moi) of 1. The
infected cell cultures were transfected with plasmid
using Lipofectin or Lipofectamine (GibcoBRL) as per
the manufacturer’s instructions. Recombinant viruses
expressing GPT were selected for mycophenolic acid
resistance in MEM containing 10% dialyzed fetal calf
serum (or no fetal calf serum), 5–20 Ag/ml mycophe-
nolic acid, 250 Ag/ml xanthine, 15 Ag/ml hypoxanthine,
2 Ag/ml aminopterin, and 10 Ag/ml thymidine. After
the initial transformations, three to six rounds of
plaque purification were undertaken and the plaques
checked for recombinant virus by PCR using primers
and conditions that provided an amplification product
specific to the recombinant virus or wild-type virus.
The following primers and conditions were used for
screening for the SLS-p28m-IL-4 recombinant virus
purity. Wild-type virus detection used primers designat-
ed MJ2a-R2 from the M062 gene (ATCGTAGGG-
TATTCGCACG) and TK-F2 (GATATCCGAACACGTC-
GAAG) from the M061 gene. These primers produce a
700-bp amplification product from wild-type virus se-
quence. The extension times used did not allow ampli-
fication across the recombinant sequence from these
primers. Primers MJ2a-R2 and IL-4-star t -Bgl
(GCAAGATCTATGGGGCTCCCTGCCCAG -sequence
match ing IL-4 i s unde r l ined the rema in ing
sequence is a BglI site used for other cloning steps)
were used to detect recombinant virus. These primers
produce a 900-bp amplification product. Amplification
conditions were as follows: cycle 1 (1) 95 jC/2 min;
cycle 2 (35) 95 jC/30 s; 56 jC/30 s; 72 jC/45 s;
cycle 3 (1) 72 jC/3 min). For Ur-pZPB-p28m-IL-4
detection and SLS-slp-IL-4 detection the following pri-
mers were used: IL-4-start-Bgl and IL-4-stop-spe
(TTAACTAGTTCAGCTCTGACGCTTTGAG). This
primer pair produces a 462-bp product. Wild-type virus
was detected using primers BI2 (CAACCTAATCG-
TAAATATCCG) from just 5V to the M062 start codon
and TK-F2, which produce a 358-bp product. The PCR
cycle conditions for these primer pairs were: cycle 1
(1) 95j/3min; cycle 2 (35) 95j/30 s; 55j/30 s; 72j/
90 s; cycle 3 (1) 72j/5 min.
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type virus by PCR analysis was amplified in RK13 cells and
used for subsequent experiments.
Immunoblotting
To determine that each recombinant virus was expressing
IL-4 in cell culture, RK13 cells were infected (moi of 1) in
MEM without bovine serum. After 24 h, culture super-
natants were concentrated by acetone precipitation and
resuspended in SDS-PAGE loading buffer for gel electro-
phoresis. Following electrophoretic separation, the proteins
were transferred to PVDF membranes using a semidry
transfer apparatus and probed with an antiserum to a rabbit
IL-4 synthetic peptide raised in rats. Electrophoresis and
immunoblotting were performed as previously described
(Kerr et al., 1999).
Replication kinetics of recombinant viruses
The replication kinetics of each recombinant virus were
measured by infecting confluent monolayers of RK13 cells
at moi of 3 or 0.1 in duplicate. Cell monolayers were
incubated for 75 min (37 jC, 5% CO2 in air) with the virus
inoculum, washed twice, and the growth medium replaced.
Cells and supernatant were harvested at appropriate time
points; the combination was freeze– thawed twice and
plaque-assayed on Vero cell monolayers in duplicate.
Rabbits
Laboratory rabbits were bred and housed in the CSIRO
Sustainable Ecosystems animal facility. Wild rabbits were
bred for at least two generations in the same animal facility
from breeding stock originally obtained as 4–6-week-old
kittens from the field and unexposed to myxoma virus.
Animal experimentation was approved by the CSIRO Sus-
tainable Ecosystems Animal Experimentation Ethics Com-
mittee. All experiments with recombinant viruses were
conducted under containment level 2 conditions under
license from the Commonwealth of Australia Office of the
Gene Technology Regulator.
Virulence trials
Groups of 5–12 rabbits >4 months of age were housed in
individual cages and inoculated intradermally in the thigh
with 1000 pfu of virus in a volume of 100 Al. Rabbits were
examined twice a day. Clinical signs and rectal temperatures
were recorded at 24-h intervals after inoculation. Survival
times were allocated based on the nearest 0.25 days. Rabbits
that were moribund were euthanized with intravenous barbi-
turate. If a rabbit was euthanized, an extra 0.5 day was
arbitrarily added to the survival time. Results were calculated
as average survival times (AST) and statistical differences
between AST for each group were analyzed by t test.Pathogenesis trials
To examine the pathogenesis of SLS-slp-IL-4, groups of
laboratory and wild rabbits were inoculated with 1000 pfu
of SLS-slp-IL-4 into the dorsal skin of the right hind foot
(Best and Kerr, 2000). At 2, 4, 6 and, for wild rabbits,
8 days, after infection, three rabbits were killed with
intravenous barbiturate and autopsied. The following tissues
were collected into preweighed vials on dry ice: skin from
the inoculation site, distal skin from the equivalent site on
the left (contralateral) foot, the right (draining) popliteal
lymph node, the left (contralateral) popliteal lymph node,
spleen, lung, and brain. These tissues were frozen at 70 jC
until processing. After weighing, tissues were chopped
finely and homogenized using hand-held homogenizers.
Homogenized tissues were freeze–thawed twice and soni-
cated to release virus as previously described (Best and
Kerr, 2000) before being diluted to a 10% w/v suspension in
MEM. Virus titers were measured by plaque assay on Vero
cell monolayers and expressed as pfu/g of tissue. The lowest
level of detection was 100 pfu/g.
Immunity trials
Eight laboratory rabbits were immunized with 5000 pfu
of Ur-HA injected intradermally into the right thigh. Rabbits
were allowed to recover and at 6 weeks after immunization,
four rabbits were challenged with 1000 pfu of SLS-slp-IL-4
by injection into the skin opposite the original vaccination
site. The other four were challenged with wild-type SLS.
Following this challenge, four rabbits were retained for a
further 29 weeks and then rechallenged.
Oral delivery trials
Six laboratory rabbits were dosed with 50,000 pfu of SLS-
slp-IL-4 in 200 Al of 1:1 saline/glycerol delivered into the
mouth using a Gilson Pipetman. Clinical signs of disease and
rectal temperatures were recorded daily. In a second trial, with
the same rabbits, 50,000 pfu of SLS-slp-IL-4 were delivered,
in a 10-Al volume of saline, behind the lower lip and the
rabbits monitored for clinical signs of myxomatosis. After
this trial, serum was collected from each rabbit and examined
for antibodies to myxoma virus by ELISA (Kerr, 1997).Acknowledgments
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